| アブストラクト | BACKGROUND: Treatment to prevent the recurrence of venous thromboembolism (VTE) and prevent bleeding events should be given to patients with VTE in an appropriate balance in relation to relevant predictors. We elucidated the current medical care in a real world setting and quantified predictors using a Japanese healthcare database. METHODS: The study included 3578 patients who were diagnosed with VTE between April 2008 and September 2013 at a Japanese acute-care hospital and included in the hospital database. Twenty-four patients who had a VTE event during the 180-day period after enrollment were excluded. We analyzed the incidence of recurrent VTE, incidence of bleeding events, and predictors in VTE patients. Events were defined by disease, medication, imaging, and laboratory testing, among other factors. RESULTS: The rate of recurrence of VTE events was 7.2 per 100 patient-years. The incidence rate of bleeding events was 8.3 per 100 patient-years. The presence of malignant disease, antipsychotic drugs, and nonsteroidal anti-inflammatory drugs increased the risk for recurrent VTE. The predictors for bleeding events were malignant disease, central venous catheterization, cancer chemotherapy, stroke, and diabetes. CONCLUSIONS: These findings obtained from healthcare database suggest predictors either for recurrent VTE and bleeding that should be considered when selecting treatment to reduce the risk of recurrent VTE and mitigate bleeding. |
|---|
| ジャーナル名 | Journal of cardiology |
|---|
| Pubmed追加日 | 2017/3/2 |
|---|
| 投稿者 | Nakamura, Mashio; Yamada, Norikazu; Oda, Eisei; Matsubayashi, Daisuke; Ota, Kaori; Kobayashi, Masafumi; Matsushita, Yasuyuki; Kaburagi, Jumpei; Ibusuki, Kei; Takita, Atsushi; Iwashita, Mikio; Yamaguchi, Takuhiro |
|---|
| 組織名 | Department of Cardiology and Nephrology, Mie University Graduate School of;Medicine, Tsu, Japan. Electronic address: mashio@clin.medic.mie-u.ac.jp.;Medicine, Tsu, Japan.;Medical TOUKEI Corporation, Tokyo, Japan.;Medical Data Vision Co., Ltd., Tokyo, Japan.;Department of Corporate Planning, Linical Co., Ltd., Osaka, Japan.;EU Biostatistics & Data Management, Daiichi Sankyo Europe GmbH, Munich, Germany.;Medical Science Department, Daiichi Sankyo Co Ltd., Tokyo, Japan.;Safety and Risk Management Department, Daiichi Sankyo Co Ltd., Tokyo, Japan.;Division of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi,;Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/28245956/ |
|---|
